HVB MINI FUTURE BULL - ASTRAZENECA | Real-time Bid/Ask 08:36:23 2024-06-14 am EDT | ||
| 2.71 EUR / 2.72 EUR | +5.23% |
|
| Current month | +7.95% | ||
| 1 month | +3.61% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ASTRAZENECA PLC
Latest news about ASTRAZENECA PLC
More news
| Date | Price | Change |
|---|---|---|
| 24-06-14 | 2.7 | +4.65% |
| 24-06-13 | 2.58 | -2.64% |
| 24-06-12 | 2.65 | +1.15% |
| 24-06-11 | 2.62 | -9.03% |
| 24-06-10 | 2.88 | +3.97% |
Delayed Quote Börse Stuttgart
Last update June 14, 2024 at 03:52 am EDT
More quotesStatic data
| Product type | Knock-Out with Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | ASTRAZENECA PLC |
| Issuer | 
UniCredit
|
| WKN | HD45EC |
| ISIN | DE000HD45EC7 |
| Date issued | 2024-03-26 |
| Strike | 10,203 p |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 0.61 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 2.91 € |
|---|---|
| Lowest since issue | 0.35 € |
| Spread | 0.01 € |
| Spread % | 0.37% |
Company Profile
AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows:
- product sales (95.6%). Net sales break down by treatment area between oncology (39.2%), cardiovascular, renal and metabolic diseases (24.2%), respiratory and autoimmune diseases (13.9%), and other (22.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases);
- collaboration revenue (4.4%).
Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (21.2%), America (45.3%) and Africa-Asia-Australia (26.1%).
Sector
-
Consensus: AstraZeneca PLC
Sell
Buy
Mean consensus
BUY
Number of Analysts
23
Last Close Price
158.1
USD
Average target price
174.4
USD
Spread / Average Target
+10.34%
- Stock Market
- Certificates
- Certificat
